Compare Amgen, Inc. (AMGN) vs First Trust NASDAQ Cybersecurity ETF (CIBR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs First Trust NASDAQ Cybersecurity ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while First Trust NASDAQ Cybersecurity ETF trades at $92.26. The key difference: Amgen, Inc. pays a 2.77% dividend while First Trust NASDAQ Cybersecurity ETF pays none, and First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Amgen, Inc. nearer its low. Which is the better fit depends on your goals.
| AMGN | CIBR | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $94.32 |
52-Week Low | $271.18 | $60.74 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CIBR trades at $91.88, down 2.52% today but maintains strong bullish momentum with 17 buy signals versus 5 sell signals. The cybersecurity ETF has significantly outperformed the S&P 500, delivering 22% returns since December 2025 compared to the index's 8%. Recent technical indicators show overbought conditions with RSI above 80, while moving averages remain strongly bullish. The fund benefits from growing cybersecurity spending exceeding $300 billion in 2026 and captures exposure to 30+ cybersecurity companies including CrowdStrike.
The outlook remains positive given structural growth in cybersecurity demand, though current overbought conditions suggest potential near-term consolidation. Key risks include concentrated tech exposure and valuation sensitivity. Institutional ownership continues to grow with recent filings showing significant position increases by wealth management firms, supporting the long-term investment case for digital defense exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →
